Mounjaro or tirzepatide: understanding the name, the medicine, and your options

What tirzepatide actually does in the body, and why the dual-action matters

Most GLP-1 medicines work on a single receptor pathway. Tirzepatide activates two: GLP-1 and GIP, both of which play a role in appetite signalling, blood-sugar regulation, and how quickly food moves through the stomach. Activating both pathways at once appears to produce greater appetite reduction than either alone, which is the biological reason the trial results stand out.

It is worth setting aside one misconception that circulates online: that Mounjaro is simply a higher dose of Wegovy or Ozempic. It is not. Semaglutide (Wegovy, Ozempic) targets GLP-1 only. Tirzepatide is a structurally different molecule with a different receptor profile, which is why people often ask whether it is the same as Mounjaro. The distinction matters when you and a prescriber are weighing options, because the side-effect profiles, the titration schedules, and the clinical evidence all differ between the two.

The evidence base for tirzepatide comes from the SURMOUNT programme. SURMOUNT-1 enrolled 2,539 adults with obesity and no diabetes; at 72 weeks the 15 mg group had lost an average of around 20–21% of body weight. A later head-to-head trial, SURMOUNT-5, compared tirzepatide directly with semaglutide 2.4 mg and found greater average weight reduction with tirzepatide, as noted in NICE's technology appraisal TA1026. These figures describe populations in controlled trials; individual results vary and a prescriber will set realistic expectations based on your own circumstances.

Who the licence covers, and what eligibility actually involves

The UK licence for Mounjaro covers adults managing their weight alongside a reduced-calorie diet and increased physical activity. The starting point is a BMI of 30 or above, or a BMI of 27 or above where at least one weight-related health condition is present, such as high blood pressure, high cholesterol, prediabetes, type 2 diabetes, or obstructive sleep apnoea. Lower BMI thresholds apply for people from South Asian, Chinese, Middle Eastern, Black African, or African-Caribbean backgrounds under UK guidance.

NICE recommends tirzepatide on the NHS for adults with a BMI of 35 or above plus at least one weight-related comorbidity, with phased rollout criteria that have been tightening the eligibility gate as NHS capacity grows. The private licensed eligibility is broader, which is why many people come to a service like ours before they meet NHS criteria or while waiting lists are long.

A BMI figure alone does not determine suitability. The prescriber looks at the whole picture: current medications, medical history, relevant conditions, and whether anything in your history requires a more cautious approach. People who are pregnant, breastfeeding, or actively trying to conceive are advised against this treatment, as are those under 18. Certain thyroid conditions and a personal or family history of medullary thyroid carcinoma are also relevant factors the prescriber will ask about. The NHS tirzepatide medicines page sets out the full contraindications clearly and is worth reading before a consultation.

Side effects to know about before you decide

Gastrointestinal effects are the most common experience. Nausea, loose stools, constipation, indigestion, and a feeling of fullness that lingers longer than expected all appear in the trial data. For most people these are most noticeable in the first few weeks after starting or stepping up to a new dose, and they settle as the body adjusts. Starting on the 10 mg dose, or on the lower introductory strengths used during titration, is part of how the side-effect burden is managed in the early weeks. Eating smaller portions, staying hydrated, and avoiding rich or fatty meals during the early weeks tends to help.

Less common but worth knowing: in January 2026 the MHRA issued a Drug Safety Update highlighting acute pancreatitis as a known, infrequent but potentially serious side effect of GLP-1 class medicines. Severe stomach pain that extends to the back and does not pass needs prompt medical attention rather than waiting to see if it resolves. The Yellow Card scheme at yellowcard.mhra.gov.uk is how patients and healthcare professionals report suspected side effects in the UK, and it is the mechanism that keeps the post-market safety picture up to date.

If you are taking an oral contraceptive pill, the prescriber will advise adding a barrier method for the first four weeks of treatment and for four weeks after each dose increase, because tirzepatide's effect on gastric emptying may reduce how well the pill is absorbed. That is a practical detail that catches people off guard, so it is worth raising at the start. If you would like a broader look at how costs compare across providers before speaking to a clinician, our Mounjaro price comparison guide covers what to look for.

How to approach the actual decision

The decision is not really Mounjaro or tirzepatide, because those are the same thing. The real questions are: does this medicine suit my health profile, is now the right time to start, and am I choosing a provider with the clinical oversight to support me safely through the full tirzepatide treatment journey, including later maintenance phases?

On that last point, some practical checks matter. Any legitimate supplier of a prescription-only medicine in the UK must involve a prescriber who has assessed you, and you should be able to verify their pharmacy on the GPhC register. Sellers offering these medicines without a proper clinical assessment are a red flag; the MHRA has seized large quantities of counterfeit pens sold online, and people seeking the higher 30 mg strength in particular have been targeted by unregulated sources, with serious consequences for the people who used them.

At nume, every consultation is read by a GPhC-registered Independent Prescriber who considers your full health picture before making any decision. There is no algorithm making that call. Our clinical team oversees all prescribing, and you can read more about who we are before you begin. If you have questions not covered here, our FAQs page addresses the ones we hear most often, and our team is reachable through the contact page seven days a week. For a broader look at what treatment involves from the start, the weight-loss treatment overview is a useful next step. When you are ready, check your eligibility with a free consultation.